

Atsushi Mizokami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5097286/publications.pdf>

Version: 2024-02-01

117
papers

2,956
citations

201385

27
h-index

197535

49
g-index

120
all docs

120
docs citations

120
times ranked

3742
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen Receptor: An Overview. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 1995, 5, 97-125.	0.4	260
2	Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. <i>EMBO Molecular Medicine</i> , 2013, 5, 1383-1401.	3.3	199
3	The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. <i>Cancer Research</i> , 2004, 64, 765-771.	0.4	164
4	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. <i>Prostate</i> , 2007, 67, 955-967.	1.2	130
5	The CCL20-CCR6 Axis in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5186.	1.8	124
6	Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. <i>Oncotarget</i> , 2017, 8, 9739-9751.	0.8	98
7	TUMOR NECROSIS FACTOR- β REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE. <i>Journal of Urology</i> , 2000, 164, 800-805.	0.2	80
8	Macrophage Polarity and Disease Control. <i>International Journal of Molecular Sciences</i> , 2022, 23, 144.	1.8	80
9	Exosome-derived microRNAs contribute to prostate cancer chemoresistance. <i>International Journal of Oncology</i> , 2016, 49, 838-846.	1.4	74
10	Notch Pathway Inhibition Using PF-03084014, a γ -Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4619-4629.	3.2	73
11	Tumor necrosis factor- β induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. <i>Cancer Science</i> , 2018, 109, 1524-1531.	1.7	72
12	Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. <i>Chinese Journal of Cancer</i> , 2017, 36, 35.	4.9	63
13	The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 8818-8825.	0.4	62
14	Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. <i>Endocrine-Related Cancer</i> , 2009, 16, 1139-1155.	1.6	59
15	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8530.	1.8	50
16	[^{14}C]Fluciclovine (alias anti-[^{14}C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. <i>Nuclear Medicine and Biology</i> , 2015, 42, 887-892.	0.3	46
17	Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 668-673.	0.5	46
18	Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. <i>EMBO Molecular Medicine</i> , 2022, 14, e14903.	3.3	46

#	ARTICLE	IF	CITATIONS
19	Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β 1-associated osteoblastic changes. <i>Prostate</i> , 2009, 69, 1222-1234.	1.2	45
20	Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. <i>Annals of Nuclear Medicine</i> , 2013, 27, 802-807.	1.2	45
21	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. <i>Cancer Science</i> , 2019, 110, 279-288.	1.7	40
22	Testosterone and Bone Health in Men: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 530.	1.0	39
23	Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1413-1419.	1.2	35
24	Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. <i>Oncotarget</i> , 2016, 7, 8389-8398.	0.8	34
25	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. <i>Cancers</i> , 2020, 12, 89.	1.7	33
26	Skp2 is associated with paclitaxel resistance in prostate cancer cells. <i>Oncology Reports</i> , 2016, 36, 559-566.	1.2	30
27	Cxcl5 motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. <i>Cancer Science</i> , 2018, 109, 724-731.	1.7	29
28	Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. <i>Prostate</i> , 2019, 79, 468-479.	1.2	29
29	Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 1064-1068.	0.5	28
30	Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9328.	1.8	27
31	Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. <i>International Journal of Urology</i> , 2010, 17, 337-345.	0.5	26
32	Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 3604-3611.	1.2	26
33	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018, 9, 16185-16196.	0.8	26
34	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 1290-1301.	1.5	25
35	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. <i>Prostate</i> , 2010, 70, 48-60.	1.2	24
36	Reconsideration of progression to CRPC during androgen deprivation therapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 164-171.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. <i>Prostate</i> , 2018, 78, 849-856.	1.2	23
38	Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. <i>Asian Journal of Andrology</i> , 2017, 19, 143.	0.8	23
39	Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. <i>Anticancer Research</i> , 2010, 30, 5201-5.	0.5	23
40	Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. <i>International Journal of Urology</i> , 2017, 24, 566-572.	0.5	22
41	Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 5891-5902.	1.3	22
42	Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 354.	1.0	22
43	Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth. <i>Oncotarget</i> , 2018, 9, 10510-10524.	0.8	22
44	Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. <i>International Journal of Urology</i> , 2007, 14, 233-239.	0.5	20
45	Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). <i>Aging Male</i> , 2017, 20, 1-7.	0.9	20
46	Long-term exposure of tumor necrosis factor α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. <i>Prostate</i> , 2001, 46, 319-326.	1.2	19
47	Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. <i>Annals of Nuclear Medicine</i> , 2017, 31, 201-210.	1.2	19
48	Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. <i>World Journal of Urology</i> , 2016, 34, 261-267.	1.2	18
49	Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 173-180.	1.0	18
50	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	1.6	16
51	Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 72-80.	1.2	15
52	5-Chloro-2,2-dihydroxychalcone and related flavanoids as treatments for prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1143-1152.	2.6	14
53	Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. <i>Oncotarget</i> , 2018, 9, 9206-9218.	0.8	13
54	Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. <i>Biomedicines</i> , 2021, 9, 414.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. <i>International Journal of Urology</i> , 2021, 28, 955-963.	0.5	12
56	Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. <i>International Journal of Clinical Oncology</i> , 2013, 18, 306-313.	1.0	11
57	Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. <i>Anticancer Research</i> , 2019, 39, 2553-2559.	0.5	11
58	Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: A subanalysis of a prospective randomised controlled study in Japan (EARTH study). <i>Andrologia</i> , 2020, 52, e13768.	1.0	11
59	Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. <i>Molecular Cancer Research</i> , 2017, 15, 457-466.	1.5	10
60	Three-Dimensional Analysis of Busulfan-Induced Spermatogenesis Disorder in Mice. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609278.	1.8	10
61	Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2021, 21, 1223.	1.1	10
62	Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). <i>International Journal of Urology</i> , 2022, 29, 632-638.	0.5	10
63	VARIATION IN THE ANTIANDROGENIC ACTIVITY OF DIESEL EXHAUST PARTICULATES EMITTED UNDER DIFFERENT ENGINE LOADS. <i>Polycyclic Aromatic Compounds</i> , 2004, 24, 743-757.	1.4	9
64	Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer. <i>Internal Medicine</i> , 2018, 57, 3123-3128.	0.3	9
65	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. <i>Anticancer Research</i> , 2019, 39, 2607-2614.	0.5	9
66	Three-dimensional structure of seminiferous tubules in the Syrian hamster. <i>Journal of Anatomy</i> , 2021, 238, 86-95.	0.9	9
67	Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. <i>In Vivo</i> , 2021, 35, 1703-1709.	0.6	9
68	Three-dimensional structure of testis cords in mice and rats. <i>Andrology</i> , 2021, 9, 1911-1922.	1.9	9
69	Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer. <i>World Neurosurgery</i> , 2016, 91, 670.e1-670.e6.	0.7	8
70	Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. <i>World Journal of Urology</i> , 2016, 34, 319-327.	1.2	8
71	Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study. <i>International Journal of Urology</i> , 2018, 25, 492-499.	0.5	8
72	Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 4961-4964.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone. <i>Anticancer Research</i> , 2013, 33, 4453-61.	0.5	8
74	Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≥ 2.0 mg/ml). <i>Anticancer Research</i> , 2014, 34, 6739-46.	0.5	8
75	Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1). <i>Prostate International</i> , 2018, 6, 7-11.	1.2	7
76	A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells. <i>Prostate</i> , 2021, 81, 295-306.	1.2	7
77	Novel Prevention Procedure for Inguinal Hernia after Robot-Assisted Radical Prostatectomy: Results from a Prospective Randomized Trial. <i>Journal of Endourology</i> , 2019, 33, 302-308.	1.1	6
78	Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 477-486.	0.5	6
79	Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer. <i>In Vivo</i> , 2021, 35, 1247-1252.	0.6	6
80	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	1.7	6
81	Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. <i>BMC Cancer</i> , 2021, 21, 1316.	1.1	6
82	Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1629-1631.	1.0	5
83	Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 4291-4297.	0.5	5
84	\pm -Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer. <i>Molecules</i> , 2021, 26, 2812.	1.7	5
85	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 2045-2055.	0.5	5
86	Three-dimensional morphological analysis of spermatogenesis in aged mouse testes. <i>Scientific Reports</i> , 2021, 11, 23007.	1.6	5
87	Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. <i>Anticancer Research</i> , 2015, 35, 1723-8.	0.5	5
88	Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. <i>Anticancer Research</i> , 2022, 42, 1465-1475.	0.5	5
89	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	1.7	5
90	Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer. <i>In Vivo</i> , 2019, 33, 877-880.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity. <i>Japanese Journal of Radiology</i> , 2020, 38, 1197-1208.	1.0	4
92	Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer. <i>ACS Omega</i> , 2021, 6, 4842-4849.	1.6	4
93	Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. <i>World Journal of Men's Health</i> , 2020, 38, 132.	1.7	4
94	Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 37, 102628.	1.3	4
95	Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 352-359.	0.3	4
96	Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy. <i>Cancers</i> , 2022, 14, 3050.	1.7	4
97	Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 3.	0.4	3
98	Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. <i>Aging Male</i> , 2020, 23, 1210-1216.	0.9	3
99	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. <i>In Vivo</i> , 2021, 35, 2895-2899.	0.6	3
100	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	3
101	A case of adrenal lymphangioma resected laparoscopically with minimal invasiveness. <i>Urology Case Reports</i> , 2020, 33, 101400.	0.1	2
102	Durable response achieved using Pazopanib for germ tumor cells: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 48.	0.4	2
103	The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2310-2317.	1.0	2
104	Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 323-330.	0.3	2
105	Urinary Obstruction of Transplanted Kidney Caused by Uterine Adenomyosis and 2-Year Posthysterectomy Psoas Abscess in Conjunction with Transplanted Kidney. <i>Case Reports in Transplantation</i> , 2016, 2016, 1-3.	0.1	1
106	Optimal screening interval for men with low baseline prostate-specific antigen levels (≤ 1.0 ng/mL) in a prostate cancer screening program. <i>World Journal of Urology</i> , 2017, 35, 579-586.	1.2	1
107	A case of mesh erosion in the ureter eight years after a tension-free vaginal mesh surgery. <i>International Urogynecology Journal</i> , 2019, 30, 2199-2200.	0.7	1
108	Incidence and dosimetric predictive factors of late rectal toxicity after low-dose-rate brachytherapy combined with volumetric modulated arc therapy in high-risk prostate cancer at a single institution: Retrospective study. <i>Brachytherapy</i> , 2021, 20, 584-594.	0.2	1

#	ARTICLE	IF	CITATIONS
109	Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST.. Urology Journal, 2021, , .	0.3	1
110	Primary female urethral adenocarcinoma treated with high dose rate brachytherapy, external beam radiotherapy, and chemotherapy. International Cancer Conference Journal, 2014, 3, 108-111.	0.2	0
111	Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report. Journal of Medical Case Reports, 2015, 9, 261.	0.4	0
112	Efficacy of combined prophylactic use of levofloxacin and isepamicin for transrectal prostate needle biopsy: A retrospective single-center study. Journal of Infection and Chemotherapy, 2019, 25, 337-340.	0.8	0
113	Human papillomavirus 16â€“positive penile Bowenâ€™s disease involving the distal urethra: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2091898.	0.2	0
114	Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?. Journal of Robotic Surgery, 2021, , 1.	1.0	0
115	Parenchymal Suture-Assisted Inner Suture Method: Tips to Achieve a Reliable Inner Suture in Partial Nephrectomy. Videourology (New Rochelle, N Y), 2021, 35, .	0.1	0
116	Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology, 2016, 34, 167-167.	0.8	0
117	Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors. Cancer Diagnosis & Prognosis, 2021, 1, 13-17.	0.3	0